Announcements

Announcements

 
AERAS  [to 22 Sep 2018]
http://www.aeras.org/pressreleases
No new digest content identified.
 
 
BMGF – Gates Foundation  [to 22 Sep 2018]
http://www.gatesfoundation.org/Media-Center/Press-Releases
No new digest content identified.

 

Bill & Melinda Gates Medical Research Institute    [to 22 Sep 2018]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

 

CARB-X   [to 22 Sep 2018]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
09.20.2018  |
CARB-X 2017-18 Annual Report is now online
CARB-X’s second year was highlighted by a growing pipeline, global partnership and exciting science in the fight against superbugs

 
CEPI – Coalition for Epidemic Preparedness Innovations  [to 22 Sep 2018]
http://cepi.net/
No new digest content identified.

 

EDCTP    [to 22 Sep 2018]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.

 

Emory Vaccine Center    [to 22 Sep 2018]
http://www.vaccines.emory.edu/
No new digest content identified.

 

European Medicines Agency  [to 22 Sep 2018]
http://www.ema.europa.eu/ema/
21/09/2018
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 September 2018
CHMP elects new chair and recommends thirteen medicines for approval …
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) elected Harald Enzmann as its new chair at its September 2018 meeting, for a three-year mandate starting on 21 September.
This week’s meeting of the CHMP was the last plenary meeting chaired by Dr Tomas Salmonson, who retires as chair after serving for two three-year mandates, the maximum allowed by the legislation. Dr Salmonson is a senior scientific advisor at the Swedish Medical Products Agency, where he has worked since 1986. He has been a member of the CHMP for more than 18 years and has served as chair of the Committee since September 2012…

 
European Vaccine Initiative  [to 22 Sep 2018]
http://www.euvaccine.eu/news-events
No new digest content identified.
 
 
FDA [to 22 Sep 2018]
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
No new digest content identified.
 
 
Fondation Merieux  [to 22 Sep 2018]
http://www.fondation-merieux.org/
Mérieux Foundation event
Global challenges in vaccine acceptance science and programs
September 24 – 26, 2018 – Les Pensieres Center for Global Health, Veyrier du Lac (France)
 
 
Gavi [to 22 Sep 2018]
http://www.gavi.org/library/news/press-releases/
No new digest content identified.
 
 
GHIT Fund   [to 22 Sep 2018]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.

 

Global Fund [to 22 Sep 2018]
http://www.theglobalfund.org/en/news/?topic=&type=NEWS;&country=
News
More Urgency, New Funding Needed to End TB
19 September 2018
The new WHO Global Tuberculosis Report 2018 is a call to arms for the international community, coming one week before the first UN High Level Meeting on TB, the Global Fund said. Of all the world’s infectious diseases, TB is the leading killer. Approximately 10 million people fell ill with the disease in 2017, and 1.6 million of those died.

 

Hilleman Laboratories   [to 22 Sep 2018]
http://www.hillemanlabs.org/
No new digest content identified.
 
 
Human Vaccines Project   [to 22 Sep 2018]
http://www.humanvaccinesproject.org/media/press-releases/
No new digest content identified.
 
 
IAVI  [to 22 Sep 2018]
https://www.iavi.org/
No new digest content identified.

 
IFFIm
http://www.iffim.org/library/news/press-releases/
No new digest content identified.

 

IVAC  [to 22 Sep 2018]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
No new digest content identified.
 
 
IVI   [to 22 Sep 2018]
http://www.ivi.int/
No new digest content identified.
 
 
JEE Alliance  [to 22 Sep 2018]
https://www.jeealliance.org/
No new digest content identified.
 
 
MSF/Médecins Sans Frontières  [to 22 Sep 2018]
http://www.msf.org/
Selected Press Releases/Statements
Kala azar
Diagnosing, treating and researching HIV-kala azar co-infecti…
Project Update 20 Sep 2018

Snakebite
Time to strike back at snakebite and end the antivenom acc…
Report 19 Sep 2018

Central African Republic
“We simply can’t let these people down. But we remain vigil…
Interview 18 Sep 2018

Greece
Moria is in a state of emergency
Open Letter 17 Sep 2018

Greece
Self-harm and attempted suicides increasing for child …[Lesbos]
Press Release 17 Sep 2018

 
NIH  [to 22 Sep 2018]
http://www.nih.gov/news-events/news-releases
September 20, 2018
NIH launches study to test combination antibody treatment for HIV infection
September 20, 2018 — Clinical trial will evaluate whether treatment is safe for people living with HIV.

NIH funds study to prevent, treat HIV among adolescents in poor countries
September 19, 2018 — Study seeks to identify high-risk youth and get them into medical care.

Experimental nasal influenza vaccine tested in kids, teens
September 17, 2018 — NIH-supported Phase 1 trial of potential broadly protective vaccine.

Gene variations linked to severity of Zika-related birth defects, small NIH study suggests
September 17, 2018 — Highly affected children were likely to have a mother with natural variations in genes for a key enzyme.

 

PATH  [to 22 Sep 2018]
https://www.path.org/media-center/
No new digest content identified.

 

Sabin Vaccine Institute  [to 22 Sep 2018]
http://www.sabin.org/updates/pressreleases
No new digest content identified.
 
 
UNAIDS [to 22 Sep 2018]
http://www.unaids.org/en
News
19 September 2018
National human rights institutions in eastern and southern Africa emphasize the right to health

17 September 2018
World AIDS Day 2018 theme encourages everyone to know their HIV status

 

UNICEF  [to 22 Sep 2018]
https://www.unicef.org/media/press-releases
Selected Press Releases/Reports/Statements
Statement
More violence in Yemen’s Hodeidah will push children further into the abyss
Statement from UNICEF Executive Director Henrietta Fore
21/09/2018

Press release
Refugee and migrant children arriving on Greek Islands up by one-third in 2018 – UNICEF
21/09/2018

Press release
155 children left orphaned or separated from their parents in DRC’s latest Ebola outbreak – UNICEF
21/09/2018

Press release
A child under 15 dies every five seconds around the world – UN report
Children from the highest mortality countries are up to 60 times more likely to die in the first five years of life than those from the lowest mortality countries, report also says.
18/09/2018

 

Vaccine Confidence Project  [to 22 Sep 2018]
http://www.vaccineconfidence.org/
Confidence Commentary:
Fight the infectious disease in the air — ‘fake news’
Heidi Larson | 20 Sep, 2018
Thanks to Naveen Thacker for this timely commentary:
I have been a paediatrician for over three decades and have had parents come to me with many questions about their children’s health. But over the last year I have seen a new agent cause concern in parents’ minds — one that can be dangerous, even fatal…
 

Vaccine Education Center – Children’s Hospital of Philadelphia  [to 22 Sep 2018]
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.
 
 
Wellcome Trust  [to 22 Sep 2018]
https://wellcome.ac.uk/news
No new digest content identified.
 
 
The Wistar Institute   [to 22 Sep 2018]
https://www.wistar.org/news/press-releases
No new digest content identified.

 

World Organisation for Animal Health (OIE)   [to 22 Sep 2018]
http://www.oie.int/en/for-the-media/press-releases/2018/
20/09/18
Investing in biosecurity: a key step to curb the spread of animal diseases
Animal diseases, such as avian influenza or African swine fever, know no borders and can continually affect new areas. Reducing the risk is possible through the implementation of procedures designed to avoid the introduction and spread of pathogens in animal populations. Veterinary Services in collaboration with the numerous stakeholders working with animals have a key role in ensuring that appropriate biosecurity measures are in place. A recent survey conducted among OIE Members of the Europe Region shows the current challenges faced in this regard.

::::::
 
BIO    [to 22 Sep 2018]
https://www.bio.org/insights/press-release
Sep 19 2018
BIO Applauds Release of New National Biodefense Strategy
“I applaud the Administration for recognizing the importance of strengthening our national biodefense and preparedness efforts. Our nation continues to face a wide range of biological threats, and this strategy is an important step in the right direction,” Tom DiLenge, BIO  President of Advocacy, Law & Public Policy.
 
DCVMN – Developing Country Vaccine Manufacturers Network  [to 22 Sep 2018]
http://www.dcvmn.org/
No new digest content identified.
 
IFPMA   [to 22 Sep 2018]
http://www.ifpma.org/resources/news-releases/
19 September 2018
Ghana plays host to major African healthcare business integrity and ethics forum
   Over a hundred Pharma industry management and healthcare professionals, medical and scientific advisors receive training on how to implement compliance programs.
   The African Stakeholder Forum will discuss progress across Africa in raising the standards in the ethics and business integrity space.
   Part of the Forum is a session to raise awareness about the impact of fake medicines in eroding trust in the governments, healthcare professionals, patients and manufacturers.
Accra, Ghana – 18-19 September 2018 – The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) holds two-day business ethics and integrity event combining training, discussion forum and awareness raising with aim to increase the level of ethical conduct. It is broadly acknowledged that an efficient healthcare system depends on mutual trust between manufacturers of medicines and vaccines, governments and health authorities, healthcare professionals and patients. The challenge is frequently to apply business ethics and integrity into the day to day reality of the healthcare community. IFPMA is organizing the “Business Integrity Days” as part of its mission to support efforts worldwide to uphold ethical standards…

PhRMA    [to 22 Sep 2018]
http://www.phrma.org/press-room
No new digest content identified.

Industry Watch     [to 22 Sep 2018]
:: Pfizer Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
Breakthrough Therapy Designation Designed by FDA to Expedite the Development and Review of Drugs and Vaccines Which May Demonstrate Substantial Improvement Over Available Therapy1
September 20, 2018 08:00 AM Eastern Daylight Time
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) announced today that its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) candidate, PF-06482077, received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults aged 18 years and older.2 Pfizer expects to start Phase 3 trials in a few months.
“There continues to be a global health need to protect against the potentially devastating effects of invasive pneumococcal disease and pneumonia caused by additional serotypes, and we are dedicated to continue to build on our expertise in pneumococcal conjugate vaccines with this vaccine candidate.”
The FDA decision is informed by the results of the 20vPnC Phase 2 randomized, double-blind trial to evaluate the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in adults 60 through 64 years of age. Pfizer will seek to present and publish outcomes from this clinical trial at a future date.
“We look forward to continuing our dialogue with the FDA so that we can accelerate the development program of the adult indication of Pfizer’s 20-valent next-generation pneumococcal vaccine candidate,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. “There continues to be a global health need to protect against the potentially devastating effects of invasive pneumococcal disease and pneumonia caused by additional serotypes, and we are dedicated to continue to build on our expertise in pneumococcal conjugate vaccines with this vaccine candidate.”..